American College of Cardiology

MARCH 18, 2024

In this episode, the focus is on tricuspid valve disease. In this panel discussion, host Andrea Price MS, AACC brings together Marcus Burns, DNP, Kristen deAlmeida, PharmD, and Bailey Estes MSN, AGNP-C, to explore best practices related to structural heart disease.

Tricuspid 58

Tricuspid Allied Health Best Practices Nursing 58

American College of Cardiology

AUGUST 5, 2024

What are the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip system in a contemporary real-world setting?

Tricuspid 50

Tricuspid Outcomes Article 50

American College of Cardiology

OCTOBER 1, 2024

The tricuspid valve has historically received less attention compared to the valves on the left side of the heart. Tricuspid valve disease, however, is more common than previously thought, and if left untreated, it poses a significant risk of morbidity and mortality.

Tricuspid 45

Tricuspid Article 45

American College of Cardiology

MARCH 25, 2024

The following are key points to remember from a state-of-the-art review about the current status and perspectives on transcatheter treatment of the tricuspid valve (TV).

Tricuspid 53

Tricuspid Article 53

American College of Cardiology

DECEMBER 12, 2024

The goal of the TRILUMINATE Pivotal trial was to evaluate percutaneous tricuspid valve transcatheter edge-to-edge repair (TEER) compared with medical therapy among patients with symptomatic severe tricuspid regurgitation.

Tricuspid 50

Tricuspid Outcomes Article 50

European Journal of Heart Failure

NOVEMBER 26, 2024

Right ventricular reverse remodelling after transcatheter tricuspid valve intervention (TTVI). Optimal tricuspid regurgitation (TR) reduction is critical for right ventricular reverse remodelling. Mortality was analysed at 1year after transcatheter tricuspid valve intervention (TTVI).

Tricuspid 40

Tricuspid Heart Failure Exercise Research 40

American College of Cardiology

OCTOBER 30, 2024

The goal of the TRISCEND II trial was to assess the safety and efficacy of Evoque transcatheter tricuspid valve replacement (TTVR) among patients with symptomatic severe tricuspid regurgitation (TR).

Tricuspid 45

Tricuspid Article 45

American College of Cardiology

FEBRUARY 26, 2024

What are survival rates after surgical or transcatheter intervention compared to conservative management based on tricuspid regurgitation (TR) clinical stage assessed using TRI-SCORE?

Tricuspid 45

Tricuspid Article 45

American College of Cardiology

OCTOBER 1, 2024

Our cover story this month, which outlines the issues surrounding tricuspid valve (TV) dysfunction, is worth a careful read. The story highlights the etiology, diagnosis and recent evolution of treatment strategies for TV dysfunction – medical, surgical and interventional.

Tricuspid 40

Tricuspid Article 40

European Journal of Heart Failure

NOVEMBER 8, 2023

Abstract Aim Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. ASTR vs. VSTR) are lacking.

Tricuspid 40

Tricuspid Outcomes Atrial Fibrillation Pulmonary 40

Journal of Cardiovascular Electrophysiology

MARCH 7, 2024

Abstract Introduction Transvenous leads have been implicated in tricuspid valve (TV) dysfunction, but limited data are available regarding the effect of extracting leads across the TV on valve regurgitation. Methods We studied 321 patients who had echocardiographic data before and after lead extraction.

Tricuspid 40

Tricuspid Outcomes Article 40

European Journal of Heart Failure

FEBRUARY 19, 2025

Prognostic impact of severe tricuspid regurgitation (TR) in patients with atrial functional mitral regurgitation (AFMR). Abstract Aims Tricuspid regurgitation (TR) is often seen in patients with atrial functional mitral regurgitation (AFMR).

Tricuspid 40

Tricuspid Bicuspid/Mitral Atrial Fibrillation Heart Failure 40

American College of Cardiology

APRIL 10, 2025

Transcatheter tricuspid valve replacement (TTVR) may be a "feasible and effective approach" for treating high-risk patients with severe tricuspid regurgitation (TR) who have limited therapeutic options, based on one-year outcomes of the TRAVEL study.

Tricuspid 53

Tricuspid Outcomes Article 53

American College of Cardiology

FEBRUARY 12, 2025

Patients with significant tricuspid regurgitation (TR) at intermediate disease stage were more likely to survive at one year when treated via tricuspid transcatheter edge-to-edge-repair (T-TEER) when compared to patients treated conservatively, according to a study published Feb.

Tricuspid 63

Tricuspid Article 63

American College of Cardiology

OCTOBER 27, 2024

What is the clinical impact of tricuspid regurgitation (TR) reduction with tricuspid transcatheter edge-to-edge repair (T-TEER)?

Tricuspid 60

Tricuspid Outcomes Article 60

American College of Cardiology

JULY 2, 2024

Many patients with severe, symptomatic tricuspid regurgitation (TR) may also present with advanced heart failure with preserved ejection fraction (HFpEF), and treatments for each condition may impact the other condition.

Preserved Ejection Fraction 72

Preserved Ejection Fraction Tricuspid Heart Failure Article 72

DAIC

MARCH 15, 2024

His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease. He has published over 250 peer-reviewed articles and lectures extensively worldwide.

TAVR 105

TAVR Academic Education Cardiovascular Surgery 105

European Journal of Heart Failure

MARCH 11, 2024

Abstract Aims The aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge-to-edge repair (T-TEER) as a model of right ventricular (RV) volume overload relief.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Tricuspid Heart Failure Physiology 40

European Journal of Heart Failure

FEBRUARY 19, 2024

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.

Tricuspid 40

Tricuspid Heart Disease Bicuspid/Mitral Heart Valves 40

Frontiers in Cardiovascular Medicine

MARCH 19, 2024

Results A total of 36 articles were included in the systematic review analysis. 32% of CS patients had echocardiographic evidence of cardiac involvement, of which 79% involved tricuspid valve abnormalities. 32% of CS patients had echocardiographic evidence of cardiac involvement, of which 79% involved tricuspid valve abnormalities.

Heart Disease 59

Heart Disease Tricuspid Biomarkers Article 59

American College of Cardiology

JULY 24, 2024

In this week’s View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF).

Tricuspid 58

Tricuspid Heart Failure Article 58

American College of Cardiology

AUGUST 31, 2024

Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduced the severity of secondary tricuspid regurgitation (TR) and improved quality of life after one year, based on findings from the Tri.fr trial presented at ESC Congress 2024 in London.

Quality of Life 50

Quality of Life Tricuspid Article 50

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

FAT in middle-aged and old adult patients was more likely to originate from the crista terminalis, tricuspid annulus, non-coronary cusp, and para-His. Juvenile had a higher proportion of FAT originating from the left atrial appendage, the right atrial appendage, and the free or posterior wall of the right atrium. After a mean follow-up of 47.2

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

American College of Cardiology

MAY 20, 2024

A multidisciplinary care team (MDT) must balance the risks and benefits of transvenous lead extraction (TLE) vs. entrapping leads in patients with preexisting leads from cardiac implantable electronic device (CIED) being considered for orthotopic transcatheter tricuspid valve replacement (TTVR), which accounts for roughly 35% of the TTVR population, (..)

Tricuspid 60

Tricuspid Article 60

American College of Cardiology

SEPTEMBER 11, 2024

What are the 3-year outcomes of tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip implant for the treatment of severe symptomatic tricuspid regurgitation (TR)?

Tricuspid 45

Tricuspid Outcomes Article 45

Journal of Cardiovascular Electrophysiology

DECEMBER 11, 2024

ABSTRACT Introduction The suitability of high-power short-duration (HPSD) cavo-tricuspid isthmus ablation (CTI-Abl) for electrophysiology (EP) trainees, as well as the underlying mechanisms of its efficacy, remain unknown. TF-HPSD strategy created lesions with greater surface length, width, and area than those produced by the MPLD method.

Tricuspid 40

Tricuspid Electrophysiology Ablation Article 40

American College of Cardiology

OCTOBER 21, 2024

Patients with moderate or severe tricuspid regurgitation (TR) prior to undergoing TAVR or mitral transcatheter edge-to-edge repair (TEER), when compared to patients with no or mild TR, were associated with worse health status and clinical outcomes, according to a study published in JACC: Cardiovascular Interventions.

TAVR 53

TAVR Bicuspid/Mitral Tricuspid Outcomes 53

American College of Cardiology

DECEMBER 12, 2023

What is the impact of caval implantation of the TricValve system on quality of life (QOL) outcomes at 1 year among patients with severe symptomatic tricuspid regurgitation (TR)?

Quality of Life 53

Quality of Life Tricuspid Outcomes Article 53

American College of Cardiology

FEBRUARY 28, 2024

In this week’s View, Dr. Eagle covers coronary calcium scores and how they predict ASCVD risk in the presence of left main disease and diabetes.

Diabetes 56

Diabetes Tricuspid Article 56

American College of Cardiology

NOVEMBER 26, 2024

Dr. Marwick discusses the SCOT-HEART trial, patient-echo reports augmented by AI, tricuspid valve regurgitation, and more. Marwick, MD, PhD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Takeaways from 2024 in Cardiovascular (CV) Imaging.

Tricuspid 50

Tricuspid Article 50

American College of Cardiology

MARCH 27, 2024

In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.

Heart Failure 58

Heart Failure Stenosis Aortic Tricuspid 58

All About Cardiovascular System and Disorders

FEBRUARY 14, 2024

In fact the Circulation article cited is on Complete Transposition of the Great Vessels. Tricuspid atresia – ECG Right atrial overload is manifest as tall P waves in lead II and left ventricular hypertrophy with strain pattern is seen in lateral leads with tall R waves, ST segment depression and T wave inversion.

Congenital Heart Disease 52

Congenital Heart Disease Congenital Heart Disease VSD 52

American College of Cardiology

FEBRUARY 2, 2024

Food and Drug Administration (FDA) has approved the EVOQUE tricuspid valve replacement system for the treatment of tricuspid regurgitation (TR).

Tricuspid 40

Tricuspid Article 40

DAIC

MARCH 15, 2024

His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease. He has published over 250 peer-reviewed articles and lectures extensively worldwide.

TAVR 52

TAVR Academic Education Cardiovascular Surgery 52

Journal of Cardiovascular Electrophysiology

APRIL 2, 2025

In the PVI + group, extra PV ablation included left atrial posterior wall isolation (87%), mitral isthmus ablation (37%), and cavo-tricuspid isthmus ablation (3%). Results The study included 448 patients (347 PVI only, 101 PVI + ).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Tricuspid 40

Journal of Cardiovascular Electrophysiology

DECEMBER 16, 2024

All patients demonstrated a significant decrease in LVEDD as well as a reduction in severity of mitral and tricuspid regurgitation during 1 year after LVAD implantation, reflecting left ventricular unloading through the LVAD.

Defibrillator 40

Defibrillator Arrhythmia Tricuspid Bicuspid/Mitral 40

Journal of Cardiovascular Pharmacology

MARCH 13, 2024

MCT group showed increase in RV hypertrophy, RV systolic area, RV systolic, mean pulmonary artery pressure (mPAP), and pulmonary vascular resistance (PVR), while exhibited a decrease in RV outflow tract AT/ET ratio, RV fractional shortening and tricuspid annular plane systolic excursion (TAPSE) compared to CTR (P<0.05).

Pulmonary 40

Pulmonary Hypertension Tricuspid Cardiac Function 40